Bowel Cancer Clinical Trials
Here are the 6 most popular medical studies for bowel cancer
PD-L1 Inhibitor
Durvalumab + Olaparib + Cediranib for Advanced Solid Tumors and Breast Cancer
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Tyrosine Kinase Inhibitor
Paclitaxel + Nilotinib for Peritoneal Carcinomatosis and Gynecologic Cancers
This trial is testing a combination of oral nilotinib plus paclitaxel given by IV and directly into the abdomen to see if it can reduce tumors enough for people to have surgery.
Fleet Enema vs Pico-Salax for Colorectal Cancer Surgery
This trial will compare the effectiveness of two different methods of bowel preparation before transanal endoscopic surgery - Fleet enemas and Pico Salax oral mechanical bowel preparation - in cleansing the rectum, as measured by a modified version of the Ottawa Bowel Prep Scale.
Popular filter options for bowel cancer trials
Colorectal Cancer Clinical Trials
View 33 Colorectal Cancer medical studies.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
CAR T-cell Therapy
TC-510 for Mesothelin-Expressing Cancer
This trial is testing a new cell therapy for cancer that uses genetically engineered T cells. The T cells are modified to express two synthetic constructs: a single-domain antibody that recognizes human Mesothelin, and a PD-1:CD28 switch receptor. The PD-1:CD28 switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
Adenomatous Polyposis Clinical Trials
View 33 Adenomatous Polyposis medical studies.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
CAR T-cell Therapy
TC-510 for Mesothelin-Expressing Cancer
This trial is testing a new cell therapy for cancer that uses genetically engineered T cells. The T cells are modified to express two synthetic constructs: a single-domain antibody that recognizes human Mesothelin, and a PD-1:CD28 switch receptor. The PD-1:CD28 switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
Metastatic Bowel Cancer Clinical Trials
View 34 metastatic bowel cancer medical studies.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
Antibody-Drug Conjugate
Tisotumab Vedotin + Pembrolizumab + Carboplatin + Cisplatin for Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are four parts to this study.
Bowel Cancer Clinical Trials With No Placebo
View 34 bowel cancer medical studies that do not have a placebo group.
Monoclonal Antibodies
SGN-CEACAM5C for Stomach Tumors
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called SGN-CEACAM5C. SGN-CEACAM5C is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of SGN-CEACAM5C in participants with solid tumors that are hard to treat or have spread throughout the body. This study will have 3 parts. Part A and Part B of the study will find out how much SGN-CEACAM5C should be given to participants. Part C will use the information from Parts A and B to see if SGN-CEACAM5C is safe and if it works to treat solid tumor cancers.
CAR T-cell Therapy
TC-510 for Mesothelin-Expressing Cancer
This trial is testing a new cell therapy for cancer that uses genetically engineered T cells. The T cells are modified to express two synthetic constructs: a single-domain antibody that recognizes human Mesothelin, and a PD-1:CD28 switch receptor. The PD-1:CD28 switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.
View More Bowel Cancer Trials
See another 12 many medical studies focused on bowel cancer.
Frequently Asked Questions
Introduction to bowel cancer
What are the top hospitals conducting bowel cancer research?
When it comes to cutting-edge clinical trials in the battle against bowel cancer, several top hospitals are making notable contributions. In New York City, Memorial Sloan Kettering Cancer Center leads the way with six active trials specifically focused on this condition, in addition to an impressive history of 70 completed trials spanning several decades since their first recorded bowel cancer trial in 1989. Moving over to Boston, Massachusettst bowel cancer, several top hospitals are making notable contributions. In New York City, Memorial Sloan Kettering Cancer Center leads the way with six active trials specifically focused on this condition, in addition to an impressive history of 70 completed trials spanning several decades since their first recorded bowel cancer trial in 1989. Moving over to Boston, Massachusetts General Hospital is also actively involved in advancing research for bowel cancer with four ongoing trials and a remarkable record of 71 completed studies since their inaugural trial in 2001.
Further south at Duke University Medical Center in Durham, researchers are currently conducting three active clinical trials for bowel cancer while having made significant progress through 33 previous investigations since initiating their first study back in 2003. Meanwhile, the National Institutes of Health Clinical Center located in Bethesda contributes its expertise as well, engaging four ongoing bowel cancer trials and contributing knowledge from a total of fourteen accomplished studies ever since they commenced research efforts targeting this disease back in1999.
Despite being relatively new to the scene compared to other institutions on this list, Norton Cancer Institute situated within Louisville plays a vital role by offering three current clinical trials for bowel cancer patients. Although still building up its portfolio with only four previously conducted investigations thus far (beginning just three years ago), Norton Cancer Institute shows great promise and dedication towards pushing boundaries for improved outcomes.
These leading hospitals collectively serve as beacons of hope not only for those affected by bowel cancer but also symbols of progress within the medical field globally. Each trial carried out brings us closer to understanding this complex disease better and developing more effective treatments that can potentially save lives around the world
Which are the best cities for bowel cancer clinical trials?
When it comes to bowel cancer clinical trials, several cities in the United States offer significant opportunities for research and advancements. Los Angeles, California leads with 18 active trials focusing on treatments like Eflornithine plus sulindac, tucatinib, and Ramucirumab. New York, New York follows closely behind with 17 ongoing studies exploring innovative approaches such as pralsetinib (BLU-667), GRT-C901, and Botensilimab/balstilimab (bot/bal). Additionally, Boston, Massachusettso bowel cancer clinical trials, several cities in the United States offer significant opportunities for research and advancements. Los Angeles, California leads with 18 active trials focusing on treatments like Eflornithine plus sulindac, tucatinib, and Ramucirumab. New York, New York follows closely behind with 17 ongoing studies exploring innovative approaches such as pralsetinib (BLU-667), GRT-C901, and Botensilimab/balstilimab (bot/bal). Additionally, Boston, Massachusetts contributes to the field with 11 active trials investigating JDQ443+trametinib and NUC-3373 among others. These cities serve as hubs of medical research for bowel cancer clinical trials that hold promise for improving treatment options and outcomes.
Which are the top treatments for bowel cancer being explored in clinical trials?
Bowel cancer research is steadily progressing, with a few promising treatments currently under exploration in clinical trials. One of the top contenders is tucatinib, which has one active trial and three all-time bowel cancere all-time bowel cancer trials since its listing in 2020. Another treatment being investigated is ELU001, also with one ongoing trial and one all-time bowel cancer trial that was first listed in 2021. Additionally, EU101 shows potential as it enters the scene with one active trial and one all-time bowel cancer trial from 2021 onwards. As these trials progress, there is hope for advancements in treating this challenging disease.
What are the most recent clinical trials for bowel cancer?
Exciting advancements are being made in the field of bowel cancer research, with recent clinical trials exploring innovative approaches to treatment. A noteworthy trial is A2530, a combined Phase 1 and Phase 2 study that became available on 4/28/2023. Another promising investigation involves NUFIRI-bev administered on a Q1W NUC-3373 schedule for bowel cancer patients—this Phase 2 trial was accessible from 4/18/2023. Additionally, researchers have been studying the potential benefits of botensilimab and balstilimab (bot/bal) in treating bowel cancer in a separate Phase 2 trial initiated on 3/17/2023. These studies highlight the dedication to finding more effective therapies for those impacted by this disease.
What bowel cancer clinical trials were recently completed?
Recent clinical trials have made significant strides in advancing the treatment of bowel cancer. One noteworthy trial, sponsored by Mayo Clinic, focused on evaluating the efficacy of the Colorectal Cancerf bowel cancer. One noteworthy trial, sponsored by Mayo Clinic, focused on evaluating the efficacy of the Colorectal Cancer Peptide Vaccine PolyPEPI1018 and was completed in January 2022. Another study conducted by Janssen Research & Development, LLC investigated JNJ-64251330 and concluded in November 2021. Additionally, Apros Therapeutics' APR003 trial reached completion in January 2021. These studies represent important contributions to our understanding of bowel cancer therapies and offer hope for improved treatments for patients battling this disease.